http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes
Mongiorgi, Sara,Finelli, Carlo,Yang, Yong Ryoul,Clissa, Cristina,McCubrey, James A.,Billi, Anna Maria,Manzoli, Lucia,Suh, Pann-Ghill,Cocco, Lucio,Follo, Matilde Y. Informa UK (Ashley Publications) 2016 Expert opinion on therapeutic targets Vol.20 No.6
What should be considered on design of a colon-specific prodrug?
Jung, Yunjin,Kim, Young Mi Informa UK (Ashley Publications) 2010 Expert opinion on drug delivery Vol.7 No.2
<P>IMPORTANCE OF THE FIELD: Generally, a prodrug, a pharmacologically inactive derivative of an active drug, is designed to modulate pharmacokinetic properties of the parent drug. Targeted distribution of an orally administered drug at the large intestine confers therapeutic advantages on treatment of colonic diseases, peptide and protein therapy and chronotherapy. AREAS COVERED IN THIS REVIEW: To achieve such distribution control in the gastrointestinal tract, the adoption of the prodrug concept gives birth to a colon-specific prodrug. The requirement for a prodrug to be colon-specific is described along with the necessary and sufficient conditions of drugs for conversion to a colon-specific prodrug. The known and previously unnoticed factors that negatively influence therapeutic activity and reproducibility of a colon-specific prodrug are presented with suggestions to minimize the negative influence. WHAT THE READER WILL GAIN: This review provides tactics to satisfy the requirements for being colon-specific and the potential strategies to circumvent obstacles in developing an efficient colon-specific prodrug. TAKE HOME MESSAGE: On design of a colon-specific prodrug, one should take into consideration not only delivery of a drug to the target site, but also the therapeutic effectiveness there.</P>
Kim, Dae-Sun,Nam, Jae-Hwan Informa UK (Ashley Publications) 2010 Expert opinion on biological therapy Vol.10 No.2
<P>Coxsackievirus strain CVB3 is widespread in the human population and causes myocarditis or pancreatitis. However, despite its clinical impact, there is no commercially available and clinically applicable prophylactic vaccine. This study examines the characteristics of attenuated CVB3 strains developed so far and their application as live-attenuated CVB3 vaccines, and discusses problems to be overcome in the development of live-attenuated vaccines.</P>
Paroxetine mesylate: comparable to paroxetine hydrochloride?
Pae, Chi-Un,Misra, Aayushman,Ham, Byung-Joo,Han, Changsu,Patkar, Ashwin A,Masand, Prakash S Informa UK (Ashley Publications) 2010 Expert opinion on pharmacotherapy Vol.11 No.2
<P>IMPORTANCE OF THE FIELD: Currently available small case reports clearly propose that existing regulatory procedures to approve generic versions only require essential bioequivalence, have limitations and fail to meet stricter scientific and clinical demands. AREAS COVERED IN THIS REVIEW: Data indicate that paroxetine mesylate has some potential differences in bio- and clinical equivalence compared with paroxetine hydrochloride, although it has not been fully and sufficiently investigated in well-designed clinical trials. Data available now regarding safety, tolerability, efficacy and practical issues dealing with debates between generic and brand-name products paroxetine mesylate and paroxetine hydrochloride are presented in the review. WHAT THE READER WILL GAIN: Preclinical and clinical data are reviewed, and clinical issues relating to use of generic version versus original product are comprehensively discussed; tips for the clinician in clinical practice are also provided. TAKE HOME MESSAGE: Potential differences in efficacy and safety but also reduction in the use of health care and in pharmacy cost should be considered when choosing the generic version or the original product based on the clear benefit-risk ratio in patients.</P>
Development of targeted oncolytic virotherapeutics through translational research
Liu, Ta-Chiang,Hwang, Tae-Ho,Bell, John C,Kirn, David H Informa UK (Ashley Publications) 2008 Expert opinion on biological therapy Vol.8 No.9
<P>BACKGROUND: Oncolytic virotherapeutics is a promising platform for cancer treatment but the product class has yet been successful. The key to success is integration of bidirectional translational research to rapidly address issues encountered in the laboratory and the clinics. OBJECTIVE: We highlight the hurdles identified for the targeted oncolytic virotherapy approach, specifically those identified in clinical trials with wild-type viruses and first-generation targeted agents. We also analyze the translational research and development that has been applied to overcome these hurdles, including virus engineering and design improvements for next-generation virotherapeutics. RESULTS/CONCLUSION: The iterative loop between the clinic and the lab can function as a major driving force to optimize products from this platform.</P>